Innocan Pharma Secures Patent for Innovative Liposomal CBD Injection in Japan

In the latest development from Innocan Pharma Corporation (CSE: INNO), a pioneering player in the pharmaceutical and biotechnology sectors, the company has received approval for its patent on LPT-CBD, which stands for Liposomal CBD Injection Technology, in Japan. This momentous achievement highlights Innocan's commitment to advancing innovative solutions for chronic pain management in one of the world's largest pharmaceutical markets.

What is LPT-CBD?

LPT-CBD is a liposome-based formulation designed to facilitate the controlled and sustained release of synthetic Cannabidiol (CBD) into the bloodstream. This allows for ongoing relief from chronic pain, aiming to enhance the bioavailability and therapeutic effects of CBD significantly. The recently allowed patent is expected to be granted formally once the necessary administrative procedures are completed. It adds to the firm’s existing patent approvals, including a notable grant in India, which enhances Innocan's global intellectual property portfolio, ensuring robust protections across multiple jurisdictions.

A Major Milestone in the Pharmaceutical Market

Japan boasts the third-largest pharmaceutical market worldwide, valued at approximately $102 billion. Securing this patent represents a critical milestone for Innocan, reinforcing its position in the competitive landscape of pharmaceutical innovation. The LPT-CBD formulation aims to stand out as a leading non-opioid solution, presenting a safer alternative for chronic pain management, significantly reducing reliance on traditional opioid medications.

Collaboration and Development

The innovation behind LPT-CBD is the result of collaborative efforts with esteemed researchers including Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem. Together, they have developed a drug delivery platform that maximizes CBD's therapeutic potential. Promising preclinical studies have shown LPT-CBD's efficacy, with pain relief effects lasting up to four weeks. Furthermore, following a successful meeting with the U.S. Food and Drug Administration (FDA), the company received positive feedback to continue progressing toward FDA approval for this groundbreaking product.

Statements from Leadership

Iris Bincovich, the Chief Executive Officer of Innocan Pharma, expressed enthusiasm over the patent allowance, stating, "We are thrilled to receive this patent allowance for our proprietary technology. This achievement not only strengthens our intellectual property position but also serves as a testament to our commitment to innovation. We are eager for more patents to follow suit globally." Professor Chezy Barenholz added, "This patent allowance underscores the dedication and expertise of our team. LPT-CBD is a pivotal product in our development pipeline, and it's exciting to see it advance towards market availability."

Dr. Eyal Kalo, the Vice President of Research and Development, emphasized the streamlined development plan for LPT-CBD, reiterating the company's dedication to creating non-opioid alternatives for chronic pain treatment.

Conclusion

The allowance of the LPT-CBD patent not only signifies a leap forward for Innocan Pharma in the Japanese market but also reflects the company's broader ambition of enhancing global health solutions. As the world seeks safer alternatives to manage chronic pain, innovations like LPT-CBD highlight the potential of pharmaceutical advancements in addressing public health challenges globally. With ongoing research and upcoming patent approvals, Innocan is poised to make significant contributions in the realm of pain management and CBD therapeutics.